Refsum's disease: Difference between revisions
No edit summary |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 16: | Line 16: | ||
{{CMG}} | {{CMG}} | ||
'''Refsum's disease''' (Refsum-Thiébaut disease, Refsum-Thiébaut-Klenk-Kahlke disease), named after Norwegian neurologist Sigvald Bernhard Refsum (1907-1991),<ref>S. Refsum: "Heredoataxia hemeralopica polyneuritiformis - et tidligere ikke beskrevet familiært syndrom? En foreløbig meddelelse." Nordisk Medicin,1945, 28: 2682-2686 (in norwegian).</ref><ref>S. Refsum: "Heredopathia atactica polyneuritiformis. A familial syndrome not hitherto described. A contribution to the clinical study of hereditary diseases of the nervous system". Acta psych. neur., 1946. Suppl.38: 1-303.</ref> is neurological disease that results in the malformation of [[myelin]] sheaths around [[neuron|nerve cells]]. It is a [[peroxisomal disorder]]. | '''Refsum's disease''' (Refsum-Thiébaut disease, Refsum-Thiébaut-Klenk-Kahlke disease), named after Norwegian neurologist Sigvald Bernhard Refsum (1907-1991),<ref>S. Refsum: "Heredoataxia hemeralopica polyneuritiformis - et tidligere ikke beskrevet familiært syndrom? En foreløbig meddelelse." Nordisk Medicin,1945, 28: 2682-2686 (in norwegian).</ref><ref>S. Refsum: "Heredopathia atactica polyneuritiformis. A familial syndrome not hitherto described. A contribution to the clinical study of hereditary diseases of the nervous system". Acta psych. neur., 1946. Suppl.38: 1-303.</ref> is neurological disease that results in the malformation of [[myelin]] sheaths around [[neuron|nerve cells]]. It is a [[peroxisomal disorder]]. | ||
| Line 42: | Line 42: | ||
{{PNS diseases of the nervous system}} | {{PNS diseases of the nervous system}} | ||
{{Peroxisomal disorders}} | {{Peroxisomal disorders}} | ||
[[Category:Inborn errors of metabolism]] | [[Category:Inborn errors of metabolism]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
Revision as of 15:36, 20 August 2012
| Refsum's disease | |
| File:Phytanic acid.png | |
|---|---|
| Phytanic acid | |
| ICD-10 | G60.1 |
| ICD-9 | 356.3 |
| OMIM | 266500 |
| DiseasesDB | 11213 |
| eMedicine | derm/705 |
| MeSH | D012035 |
|
WikiDoc Resources for Refsum's disease |
|
Articles |
|---|
|
Most recent articles on Refsum's disease Most cited articles on Refsum's disease |
|
Media |
|
Powerpoint slides on Refsum's disease |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Refsum's disease at Clinical Trials.gov Trial results on Refsum's disease Clinical Trials on Refsum's disease at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Refsum's disease NICE Guidance on Refsum's disease
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Refsum's disease Discussion groups on Refsum's disease Patient Handouts on Refsum's disease Directions to Hospitals Treating Refsum's disease Risk calculators and risk factors for Refsum's disease
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Refsum's disease |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Refsum's disease (Refsum-Thiébaut disease, Refsum-Thiébaut-Klenk-Kahlke disease), named after Norwegian neurologist Sigvald Bernhard Refsum (1907-1991),[1][2] is neurological disease that results in the malformation of myelin sheaths around nerve cells. It is a peroxisomal disorder.
Causes
Refsum's disease is caused by faulty enzymes during the alpha-oxidation of phytanic acid resulting in buildup of phytanic acid and its unsaturated fatty acid derivatives in the plasma and tissues.
This in turn can be due to deficiencies of phytanoyl-CoA hydroxylase (chromosome 10) or peroxin-7 (chromosome 6).
Presentation
Patients with Refsum's Disease present with neurologic damage, cerebellar degeneration, and peripheral neuropathy. Onset is most commonly in childhood/adolescence with a progressive course, although periods of stagnation/remission occur.
Treatment
The most effective therapy in the classic Refsum disease is dietary treatment with a phytanic acid-restricted diet, such as exclusively avoiding consumption of beef, lamb, fatty fish such as tuna, cod, and haddock [3]. Recent research has shown that CYP4 isoform enzymes could eliminate the phytanic acid storage in vivo [4] and patients could try alternative natural remedies with either eatable marine invertebrates or with clofibrate supplement of which the component is usually rich in the excretion of high plant [5], [6], [7]. Currently, there is no clinical data to approve using this xenonbiotic drug for the treatment, perhaps due to its serious adverse effect [8]and the major medical treatment of the disease only relies on the plasmapheresis.
Reaction
Phytol (from chlorophyll in plant foods) ---> phytanic acid -x-> pristanic acid ---> propionyl CoA
See also
References
- ↑ S. Refsum: "Heredoataxia hemeralopica polyneuritiformis - et tidligere ikke beskrevet familiært syndrom? En foreløbig meddelelse." Nordisk Medicin,1945, 28: 2682-2686 (in norwegian).
- ↑ S. Refsum: "Heredopathia atactica polyneuritiformis. A familial syndrome not hitherto described. A contribution to the clinical study of hereditary diseases of the nervous system". Acta psych. neur., 1946. Suppl.38: 1-303.
- ↑ National Institutes of Health. "Synonym(s): Phytanic Acid Storage Disease, Heredopathia Atactica Polyneuritiformis <Internet>". Retrieved 8 July. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help) - ↑ Xu, Fengyun; et al. "CYP4 Isoform Specificity in the {omega}-Hydroxylation of Phytanic Acid, a Potential Route to Elimination of the Causative Agent of Refsum's Disease <Internet>". Retrieved 11 July. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help) - ↑ Snyder, Mark J. "Cytochrome P450 enzymes belonging to the CYP4 family from marine invertebrates <Internet>". Retrieved 11 July. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help) - ↑ Rewitz, Kim F. "Marine invertebrate cytochrome P450: Emerging insights from vertebrate and insect analogies <Internet>". Retrieved 11 July. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help) - ↑ Raucy, Judy L. "Regulation of CYP2E1 by Ethanol and Palmitic Acid and CYP4A11 by Clofibrate in Primary Cultures of Human Hepatocytes <Internet>". Retrieved 11 July. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help) - ↑ "Atromid-S: Indication & Dosage <Internet>". Retrieved 11 July. Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Check date values in:|accessdate=(help)
Template:PNS diseases of the nervous system Template:Peroxisomal disorders